Huang JH, Guo W, Liu Z. Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer. World J Gastroenterol 2023; 29(3): 579-581 [PMID: 36688025 DOI: 10.3748/wjg.v29.i3.579]
Corresponding Author of This Article
Zhe Liu, MD, Doctor, Professor, Surgeon, Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. liuzhe4321@126.com
Research Domain of This Article
Chemistry, Medicinal
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 21, 2023; 29(3): 579-581 Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.579
Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer
Jun-Hao Huang, Wei Guo, Zhe Liu
Jun-Hao Huang, Wei Guo, Zhe Liu, Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: Huang JH and Guo W wrote the manuscript; Liu Z edited the manuscript; and all authors have read and approved the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhe Liu, MD, Doctor, Professor, Surgeon, Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. liuzhe4321@126.com
Received: October 28, 2022 Peer-review started: October 28, 2022 First decision: November 30, 2022 Revised: December 12, 2022 Accepted: January 3, 2023 Article in press: January 3, 2023 Published online: January 21, 2023 Processing time: 76 Days and 9.2 Hours
Abstract
Pancreatic cancer is a malignant tumor with poor prognosis. The treatment of pancreatic cancer depends on the tumor stage and type, and includes local treatment (surgery, radiotherapy and ablation intervention) and systemic therapy (chemotherapy, targeted therapy and immunotherapy). We read with great interest the review “Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment” published on World J Gastroenterol and intended to share some of our perspectives in pancreatic cancer treatment. This review presents the therapeutic effects of the combination of gemcitabine and targeted drugs, which gives us a deeper insight into the combination treatments for pancreatic cancer.
Core Tip: In terms of the choice of chemotherapy regimen for pancreatic cancer, multi-drug chemotherapy is often applied in clinical practice. In general, the combination of chemotherapy and targeted therapy have better efficacy, but whether the combination of the two schemes is more effective than chemotherapy alone requires further investigations.
